Biocon
Amol Sawai is an experienced finance professional currently serving as a Cost Controller at Biocon since September 2023. Prior to this role, Amol held the position of Senior Finance Manager at Viatris from November 2020 to September 2023 and was previously a Manager at Mylan from June 2013 to November 2020. Amol's career began at Kirloskar Oil Engines Ltd as a Senior Officer from April 2007 to May 2013, where responsibilities included various aspects of financial and regulatory reporting. Amol holds a Master of Business Administration (MBA) with a focus on Finance and Financial Management Services from St. Xaviers High School, Nasik. Key expertise includes product costing, cost audit, financial reporting, and inventory valuation.
This person is not in any teams
This person is not in any offices
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.